Presentation
5 March 2021 Probing metabolic alterations in breast cancer in response to molecular inhibitors with Raman spectroscopy and validated with mass spectrometry
Author Affiliations +
Abstract
Rapid and accurate response to targeted therapies is critical to differentiate tumors that are resistant to treatment early in the regimen. In this work, we demonstrate a rapid, noninvasive, and label-free approach to evaluate treatment response to molecular inhibitors in breast cancer (BC) cells with Raman spectroscopy (RS). Metabolic reprograming in BC was probed with RS and multivariate analysis was applied to classify the cells into responsive or nonresponsive groups as a function of drug dosage, drug type, and cell type. Metabolites identified with RS were then validated with mass spectrometry. Our findings support that oncometabolites identified with RS will ultimately enable rapid drug screening in patients ensuring patients receive the most effective treatment at the earliest time point.
Conference Presentation
© (2021) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Xiaona Wen and Rizia Bardhan "Probing metabolic alterations in breast cancer in response to molecular inhibitors with Raman spectroscopy and validated with mass spectrometry", Proc. SPIE 11656, Advanced Chemical Microscopy for Life Science and Translational Medicine 2021, 1165613 (5 March 2021); https://doi.org/10.1117/12.2582004
Advertisement
Advertisement
KEYWORDS
Breast cancer

Mass spectrometry

Molecular spectroscopy

Raman spectroscopy

Remote sensing

Resistance

Therapeutics

Back to Top